New Age Alpha Advisors LLC Sells 4,828 Shares of DaVita Inc. (NYSE:DVA)

Key Points

• New Age Alpha Advisors LLC reduced its stake in DaVita Inc. by 40.5%, selling 4,828 shares and bringing its total holdings to 7,087 shares valued at approximately $1,084,000.
• Insider James O. Hearty sold 2,351 shares of DaVita stock at an average price of $150.00, resulting in a total transaction value of $352,650, decreasing his ownership by 8.28%.
• DaVita's recent earnings showed an EPS of $2.95 for the quarter, surpassing analysts' expectations and reflecting a year-over-year revenue increase of 6.1%.

New Age Alpha Advisors LLC lessened its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 40.5% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 7,087 shares of the company's stock after selling 4,828 shares during the period. New Age Alpha Advisors LLC's holdings in DaVita were worth $1,084,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of DVA. United Capital Financial Advisors LLC boosted its stake in shares of DaVita by 2.6% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock worth $361,000 after acquiring an additional 62 shares during the period. Freedom Investment Management Inc. boosted its stake in shares of DaVita by 3.6% in the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock worth $268,000 after acquiring an additional 62 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in shares of DaVita by 2.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company's stock worth $531,000 after acquiring an additional 69 shares during the period. UMB Bank n.a. boosted its stake in shares of DaVita by 65.5% in the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after acquiring an additional 76 shares during the period. Finally, Exchange Traded Concepts LLC boosted its stake in shares of DaVita by 8.9% in the first quarter. Exchange Traded Concepts LLC now owns 970 shares of the company's stock worth $148,000 after acquiring an additional 79 shares during the period. Institutional investors own 90.12% of the company's stock.

Insider Transactions at DaVita

In other DaVita news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the sale, the insider directly owned 26,038 shares in the company, valued at $3,905,700. This represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 2.00% of the stock is currently owned by company insiders.

DaVita Price Performance

NYSE:DVA opened at $127.61 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.20 and a debt-to-equity ratio of 23.18. The company has a market capitalization of $9.12 billion, a P/E ratio of 12.55, a P/E/G ratio of 0.88 and a beta of 1.09. DaVita Inc. has a 12 month low of $126.07 and a 12 month high of $179.60. The business's 50-day moving average is $140.15 and its 200 day moving average is $147.07.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. The company had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%. The firm's revenue for the quarter was up 6.1% on a year-over-year basis. During the same period in the previous year, the business earned $2.00 earnings per share. On average, equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Barclays dropped their price objective on DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research note on Thursday. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Finally, Truist Financial dropped their price objective on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday, May 19th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $170.75.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.